Valeo Financial Advisors LLC Has $6.47 Million Holdings in Amgen Inc. $AMGN

by · The Cerbat Gem

Valeo Financial Advisors LLC lowered its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 47.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 23,156 shares of the medical research company’s stock after selling 21,273 shares during the period. Valeo Financial Advisors LLC’s holdings in Amgen were worth $6,465,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Vestmark Advisory Solutions Inc. bought a new position in shares of Amgen during the 1st quarter worth about $319,000. Tocqueville Asset Management L.P. boosted its position in shares of Amgen by 3.3% during the 1st quarter. Tocqueville Asset Management L.P. now owns 20,800 shares of the medical research company’s stock worth $6,480,000 after purchasing an additional 658 shares in the last quarter. Corient IA LLC acquired a new stake in shares of Amgen in the 1st quarter valued at about $312,000. Finally, Seven Mile Advisory bought a new stake in Amgen in the 1st quarter valued at about $278,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on AMGN shares. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. DZ Bank upped their price target on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Morgan Stanley lowered their price target on Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a research report on Friday. Weiss Ratings upgraded shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Finally, Citigroup raised their price target on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $332.85.

View Our Latest Research Report on Amgen

Amgen Trading Up 0.1%

Shares of AMGN opened at $317.74 on Monday. The business’s 50-day moving average price is $316.12 and its 200-day moving average price is $298.92. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.38. The stock has a market cap of $171.10 billion, a PE ratio of 24.55, a P/E/G ratio of 2.87 and a beta of 0.45.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period in the prior year, the company earned $5.58 EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 3.2%. Amgen’s dividend payout ratio (DPR) is 73.57%.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 10,908 shares of company stock worth $3,674,966 in the last quarter. 0.69% of the stock is owned by insiders.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).